NURIX THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
NURIX THERAPEUTICS, INC. (NRIX) reported Increase (Decrease) in Accounts Payable of $1.41 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-05-31 was $1.87M.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-02-28 was -$461.00K.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-11-30 was $3.02M, a 60.12% decline year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-08-31 was $2.23M, a 103.93% increase year-over-year.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$630.00K, a 112.09% decline from fiscal 2024.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was $5.21M, a 222.74% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $1.61M, a 1798.82% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was $85.00K, a 94.65% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-05-31 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $1.41M 10-Q · filed 2026-07-09 | $4.44M derived: sum of 3 quarters · filed 2026-07-09 | $6.67M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | -$461.00K 10-Q · filed 2026-04-08 | $2.56M derived: sum of 2 quarters · filed 2026-04-08 | $4.80M derived: sum of 3 quarters · filed 2026-04-08 | $2.12M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $5.26M derived: sum of 2 quarters · filed 2026-01-28 | $2.58M derived: sum of 3 quarters · filed 2026-07-09 | -$630.00K 10-K · filed 2026-01-28 |
| 2025-08-31 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$446.00K derived: sum of 2 quarters · filed 2026-07-09 | -$3.65M 10-Q · filed 2025-10-09 | $3.93M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | -$5.89M 10-Q · filed 2026-07-09 | $1.70M derived: sum of 3 quarters · filed 2026-07-09 | $2.79M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | -$3.21M 10-Q · filed 2026-04-08 | $4.38M derived: sum of 2 quarters · filed 2026-04-08 | $5.47M derived: sum of 3 quarters · filed 2026-04-08 | $2.93M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $8.68M derived: sum of 2 quarters · filed 2026-01-28 | $6.14M derived: sum of 3 quarters · filed 2026-01-28 | $5.21M 10-K · filed 2026-01-28 |
| 2024-08-31 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | -$1.45M derived: sum of 2 quarters · filed 2025-10-09 | -$2.38M 10-Q · filed 2025-10-09 | $2.27M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | -$2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | -$3.47M 10-Q · filed 2025-07-09 | $1.18M derived: sum of 3 quarters · filed 2026-01-28 | -$18.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | -$930.00K 10-Q · filed 2025-04-08 | $3.72M derived: sum of 2 quarters · filed 2026-01-28 | $2.52M derived: sum of 3 quarters · filed 2026-01-28 | $284.00K derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.45M derived: sum of 2 quarters · filed 2026-01-28 | $1.21M derived: sum of 3 quarters · filed 2026-01-28 | $1.61M 10-K · filed 2026-01-28 |
| 2023-08-31 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | -$3.44M derived: sum of 2 quarters · filed 2024-10-11 | -$3.04M 10-Q · filed 2024-10-11 | -$3.94M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | -$2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | -$1.84M 10-Q · filed 2024-07-11 | -$2.74M derived: sum of 3 quarters · filed 2025-01-28 | -$3.50M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $400.00K 10-Q · filed 2024-04-10 | -$499.00K derived: sum of 2 quarters · filed 2025-01-28 | -$1.26M derived: sum of 3 quarters · filed 2025-01-28 | $588.00K derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$899.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$1.66M derived: sum of 2 quarters · filed 2025-01-28 | $188.00K derived: sum of 3 quarters · filed 2025-01-28 | $85.00K 10-K · filed 2025-01-28 |
| 2022-08-31 | -$763.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $1.09M derived: sum of 2 quarters · filed 2023-10-12 | $984.00K 10-Q · filed 2023-10-12 | $1.85M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $1.75M 10-Q · filed 2023-07-13 | $2.61M derived: sum of 3 quarters · filed 2023-07-13 | $1.22M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | -$103.00K 10-Q · filed 2023-04-13 | $759.00K derived: sum of 2 quarters · filed 2023-04-13 | -$633.00K derived: sum of 3 quarters · filed 2023-04-13 | $587.00K derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $862.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$530.00K derived: sum of 2 quarters · filed 2023-02-09 | $690.00K derived: sum of 3 quarters · filed 2023-02-09 | $1.59M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | -$172.00K derived: sum of 2 quarters · filed 2022-10-06 | $727.00K 10-Q · filed 2022-10-06 | $1.36M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $2.12M 10-Q · filed 2022-07-07 | $2.75M derived: sum of 3 quarters · filed 2022-07-07 | $1.61M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $899.00K 10-Q · filed 2022-04-08 | $1.53M derived: sum of 2 quarters · filed 2022-04-08 | $388.00K derived: sum of 3 quarters · filed 2022-04-08 | $1.83M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $632.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$511.00K derived: sum of 2 quarters · filed 2022-01-28 | $936.00K derived: sum of 3 quarters · filed 2022-01-28 | $1.23M 10-K · filed 2022-01-28 |
| 2020-08-31 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $304.00K derived: sum of 2 quarters · filed 2021-10-14 | $602.00K 10-Q · filed 2021-10-14 | $645.00K derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | $1.75M 10-Q · filed 2021-07-13 | $1.79M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | $298.00K 10-Q · filed 2021-04-13 | $341.00K derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $302.00K 10-K · filed 2022-01-28 | ||
| 2019-08-31 | $259.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |